Literature DB >> 16409293

Multilineage involvement of the fusion gene in patients with FIP1L1/PDGFRA-positive hypereosinophilic syndrome.

Jamie Robyn1, Steven Lemery, J Philip McCoy, Joseph Kubofcik, Yae-Jean Kim, Svetlana Pack, Thomas B Nutman, Cynthia Dunbar, Amy D Klion.   

Abstract

Myeloproliferative hypereosinophilic syndrome (MHES) is a disorder characterised by male predominance, marked eosinophilia, splenomegaly, tissue fibrosis, elevated serum tryptase and the presence of the FIP1L1/PDGFRA fusion gene in peripheral blood mononuclear cells. The characteristic hypercellular bone marrow with dysplastic eosinophils and spindle-shaped mast cells suggest that multiple lineages may be involved in the clonal process. To determine which haematopoietic lineages are involved in MHES, we purified cells of specific lineages from patients with MHES and used nested reverse transcription polymerase chain reaction (RT-PCR), quantitative RT-PCR and fluorescence in situ hybridisation to analyse the purified cell populations for the presence of the fusion gene. The fusion gene was detected in eosinophils, neutrophils, mast cells, T cells, B cells and monocytes. These results suggest that the mutation arises in a pluripotential haematopoietic progenitor cell capable of giving rise to multiple lineages. The basis for the preferential expansion of eosinophils and mast cells remains unclear.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16409293     DOI: 10.1111/j.1365-2141.2005.05863.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  16 in total

Review 1.  Eosinophilic myeloproliferative disorders.

Authors:  Amy D Klion
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2011

Review 2.  FIP1L1/PDGFR alpha-associated systemic mastocytosis.

Authors:  Yoshiyuki Yamada; Jose A Cancelas
Journal:  Int Arch Allergy Immunol       Date:  2010-06-04       Impact factor: 2.749

3.  Markers of tyrosine kinase activity in eosinophilic esophagitis: a pilot study of the FIP1L1-PDGFRα fusion gene, pERK 1/2, and pSTAT5.

Authors:  E S Dellon; J J Bower; T O Keku; X Chen; C R Miller; J T Woosley; R C Orlando; N J Shaheen
Journal:  Dis Esophagus       Date:  2011-08-05       Impact factor: 3.429

Review 4.  Systemic mast cell activation disease: the role of molecular genetic alterations in pathogenesis, heritability and diagnostics.

Authors:  Britta Haenisch; Markus M Nöthen; Gerhard J Molderings
Journal:  Immunology       Date:  2012-11       Impact factor: 7.397

Review 5.  Molecular diagnosis of mast cell disorders: a paper from the 2005 William Beaumont Hospital Symposium on Molecular Pathology.

Authors:  Cem Akin
Journal:  J Mol Diagn       Date:  2006-09       Impact factor: 5.568

Review 6.  Successful imatinib treatment of cardiac involvement of FIP1L1-PDGFRA-positive chronic eosinophilic leukemia followed by severe hepatotoxicity.

Authors:  Ayako Arai; Weihua Yan; Shihoko Wakabayashi; Shin Hayashi; Johji Inazawa; Osamu Miura
Journal:  Int J Hematol       Date:  2007-10       Impact factor: 2.490

7.  FIP1L1-PDGFRalpha imposes eosinophil lineage commitment on hematopoietic stem/progenitor cells.

Authors:  Kentaro Fukushima; Itaru Matsumura; Sachiko Ezoe; Masahiro Tokunaga; Masato Yasumi; Yusuke Satoh; Hirohiko Shibayama; Hirokazu Tanaka; Atsushi Iwama; Yuzuru Kanakura
Journal:  J Biol Chem       Date:  2009-01-14       Impact factor: 5.157

Review 8.  Eosinophilia in mast cell disease.

Authors:  Anna Kovalszki; Peter F Weller
Journal:  Immunol Allergy Clin North Am       Date:  2014-03-13       Impact factor: 3.479

9.  T-cell abnormalities are present at high frequencies in patients with hypereosinophilic syndrome.

Authors:  Grzegorz Helbig; Agata Wieczorkiewicz; Joanna Dziaczkowska-Suszek; Miroslaw Majewski; Slawomira Kyrcz-Krzemien
Journal:  Haematologica       Date:  2009-09       Impact factor: 9.941

10.  Relapse following discontinuation of imatinib mesylate therapy for FIP1L1/PDGFRA-positive chronic eosinophilic leukemia: implications for optimal dosing.

Authors:  Amy D Klion; Jamie Robyn; Irina Maric; Weiming Fu; Laura Schmid; Steven Lemery; Pierre Noel; Melissa A Law; Marilyn Hartsell; Cheryl Talar-Williams; Michael P Fay; Cynthia E Dunbar; Thomas B Nutman
Journal:  Blood       Date:  2007-08-20       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.